In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
Others have stated their priorities directly with Federal Government. Through these interviews, AHJ gives a final opportunity to communicate to all health stakeholders, the funding needs for a range of priorities. These range from new models of care to pilots and wholesale, system improvements to building more sustainable workforces to help grow certain sectors of the health system
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
- Pathology Technology Australia’s key priorities in the coming years
- Current local capability in pathology technology compared to other countries
- How the health system supports change and adoption of pathology technology
- How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
- Observations in the Strengthening Medicare Taskforce Report
And lastly Dean looks towards the Federal Budget this year and in 2024 for the adoption of currently unfunded pathology tests, that could alter pathology as a cost centre to one that saves the health system considerable money.
-
Using human skin hair follicles to treat Alzheimer’s disease
Professor Michael Valenzuela is a science opinion leader, innovator and creative thinker with a career-long commitment to the prevention and treatment of dementia.
Following that he completed graduate medicine and medical training at the Prince of Wales Hospital. In 2012, he established the Regenerative Neuroscience Group at the University of Sydney, and in 2017 became the university’s first Professor of Regenerative Medicine.
Professor Valenzuela’s group discovered a new cell type with potential for regenerative medicine, a rare neural precursor cell found deep within the human hair follicle. He is the main inventor on several related patents and is the Founder and Chief Scientific Officer of Skin2Neuron – a biotech company developing the first neurorestorative cell therapy for Alzheimer’s disease based on this work.
-
Being Part of the New Health Frontier
In November last year, the House of Representatives Standing Committee on Health, Aged Care and Sport delivered its bipartisan report “The New Frontier: Delivering better health for all Australians” on the approval processes for new drugs and novel medical technologies in Australia.
Australian Health Journal spoke to some of the industry bodies who were part of the Inquiry, for their comments on the process, the report and hopes in the recommendations being implemented.
-
Clinical entrepreneur addresses needle-phobia
Australian entrepreneur, Lauren Barber, turned her nursing background into the role of an inventor and launched a medical device into the Australian healthcare industry.
No journey is linear for an entrepreneur, but Lauren has travelled considerable distance from a nursing student to a successful entrepreneur illustration her determination and passion to help those with needle phobias. Lauren’s work with NeedleCalm is making a positive impact in the healthcare industry and improving the experiences of patients and clinicians alike.
